Emerging pharma companies face growing pressure to scale quickly while managing lean teams, limited resources and rising expectations around agentic AI. In this episode of The Top Line, Fierce Biotech host Kelly Hogan is joined by JR Raelin, executive director of analytics and insight at SynOx Therapeutics and Krishna GS, business technology solutions manager at ZS, to discuss why execution, not insight, is often the biggest challenge.
Raelin and Krishna outline common technology roadmap mistakes in first-launch and emerging organizations, including pursuing new technology and AI without strong data foundations, allowing siloed point solutions to proliferate and underinvesting in integration and interoperability. They introduce a three-horizon agentic maturity framework—from building a governed data foundation ahead of launch, through deploying execution agents that drive targeting, field alignment and omnichannel engagement, to establishing portfolio-level intelligence that converts first-launch learnings into a competitive advantage for every product that follows.
Rather than treating AI as a destination, the discussion positions agentic AI as the operating model that connects data, decisions and workflows into a single, trusted system. Drawing on their experience across biopharma and life sciences, the speakers share practical guidance on sequencing investments, embedding human oversight and explainability and connecting workflows across commercial, medical and patient teams so AI-driven insights translate into real business decisions.
The conversation examines common pitfalls, including chasing new technology and AI trends before establishing data readiness, underinvesting in integration and relying on fragmented point solutions. Raelin and Krishna explain why strong data foundations, governance and interoperability are prerequisites for and how agentic AI—when built on that foundation—can close the gap between insight and action in real commercial workflows.
Listeners will also hear a framework for scaling platforms over time, guidance on what effective implementation looks like in the first 60 to 90 days and examples of connected workflows across commercial, medical and patient functions. The episode closes with a compelling case for why the agentic roadmap is the most important strategic asset a first-launch company builds before its second product—and how getting it right converts a single launch into a portfolio intelligence engine.
Krishna GS
| Krishna GS, Sr. Manager, Business Technology - Healthcare and Life Sciences at ZSKrishna has 11+ years of experience in life sciences, working with large, mid‑size, and emerging pharmaceutical and biotech organizations. His work at ZS spans modern commercial and analytics architectures, including customer and field platforms, data and insight hubs, and AI‑enabled applications that support launch readiness, omnichannel engagement, and field performance. He partners closely with business and technology senior leadership to shape strategy, align ways of working, and architect scalable cloud and AI solutions, with increasing emphasis on generative and agentic AI in regulated settings. Recently, Krishna has focused on helping emerging biopharma companies prepare for and execute first launches by standing up the platforms, data, and governance needed to support specialty therapies and complex stakeholder ecosystems.Krishna joined ZS as an Associate and has held multiple roles of increasing responsibility at the firm. Before ZS, he worked as a software engineer at a product startup building applications to support clinical trials in drug development, giving him hands‑on experience with life sciences data, workflows, and product development in regulated environments. |
JR Raelin
| JR Raelin, Executive Director, Analytics and Insights, SynOx TherapeuticsJR is a commercial leader with over 15 years helping biopharma organizations power successful launches through strong commercial data foundations. He currently leads commercial analytics and insights at SynOx Therapeutics, where he supports high-impact disease launches by building scalable data operations platforms, governance frameworks, and analytics that translate complex data into actionable strategy.Previously, JR worked at Geron, Acceleron, and Alnylam, where he partnered with biopharma executive leaders to support launches across a range of therapeutic areas. In this capacity, he designed commercial data warehouses, BI reporting, and analytics solutions that enabled launch readiness and ongoing performance management. He has worked cross functionally with various teams including marketing, sales, patient services, market access, and medical affairs to drive data-driven decision-making across the commercial organization. |